---
layout: default
title: 7-Oxodehydroepiandrosterone 3-Acetate Adenosine Tr
parent: 僅模型預測 (L5)
nav_order: 34
evidence_level: L5
indication_count: 0
---

# 7-Oxodehydroepiandrosterone 3-Acetate Adenosine Tr
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Complex Multi-Ingredient Biological Product (16 Components): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This entry corresponds to a complex 16-ingredient product containing botanical extracts, animal organ preparations, and biological compounds, consistent with a homeopathic or organotherapy formulation.
The TxGNN model **did not generate any predicted new indications** for this product — most likely because no DrugBank ID could be assigned to the multi-ingredient mixture and individual components could not be independently mapped in the knowledge graph.
Given the complete absence of regulatory approval, mechanism data, and model predictions, **no evidence-based repurposing evaluation can be conducted at this time**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory license found) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not available; no actual studies identified |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This product contains 16 distinct components spanning three categories:

**Botanical / Herbal components**: Cynanchum vincetoxicum root, Echinacea angustifolia, Gamboge, Phytolacca americana root, Strychnos nux-vomica seed

**Animal organ preparations (organotherapy)**: Pork kidney, pork liver, pork hypothalamus (Sus scrofa hypothalamus), pork pancreas (Sus scrofa pancreas), pork insulin

**Other biological and chemical components**: 7-Oxodehydroepiandrosterone 3-acetate, adenosine triphosphate disodium, lactic acid (L-), methylcobalamin, Proteus vulgaris, graphite

This ingredient profile is consistent with a **homeopathic complex remedy** or **biological organotherapy preparation** — product classes that are fundamentally incompatible with the TxGNN repurposing pipeline for two reasons:

1. **No DrugBank ID available**: TxGNN requires a single mapped DrugBank entity as input. Multi-ingredient homeopathic mixtures cannot be mapped as a unit, and many individual components (e.g., Gamboge, graphite, Sus scrofa hypothalamus) have no DrugBank representation.
2. **No defined pharmacological mechanism**: These products do not act through a singular receptor or enzyme target pathway, making knowledge-graph traversal and disease-node linking impossible.

The query log confirms that the DrugBank lookup returned a result count of 1, but no DrugBank ID was assigned (`drugbank_id: null`), indicating an inconclusive or partial match that did not qualify for downstream prediction.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination in ClinicalTrials.gov or ICTRP.

---

## Literature Evidence

Currently no related literature available for this specific multi-ingredient combination as a single therapeutic entity.

---

## US Market Information

This product has **0 regulatory licenses** in the United States. No NDA, ANDA, or BLA records are associated with this multi-ingredient combination.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note**: Several individual components carry inherent safety concerns that would require independent review before any clinical use:
> - **Strychnos nux-vomica seed** contains strychnine and brucine — potent convulsants with a narrow therapeutic index.
> - **Gamboge** is a known GI irritant and has historically been associated with toxicity at higher doses.
> - **Phytolacca americana root** (pokeweed) contains phytolaccatoxin and has potential mitogenic and toxic effects.
> - **Pork insulin** carries risk of hypoglycaemia and immunogenic reactions.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This product is a homeopathic/organotherapy complex that the TxGNN pipeline cannot process — there is no DrugBank ID, no mapped mechanism of action, no regulatory approval, and no predicted indication. The minimum preconditions for a repurposing evaluation are not met.

**To proceed, the following is needed:**

- **Clarify product identity**: Confirm the brand name, manufacturer, and intended use category (homeopathic vs. conventional). This will determine whether the product is in scope for TxGNN-based repurposing at all.
- **Decompose into single active ingredients**: If any individual component (e.g., methylcobalamin, ATP disodium, 7-oxo-DHEA acetate) is the primary active entity, re-submit that compound as a standalone query.
- **Assess regulatory pathway separately**: Homeopathic products are regulated under distinct frameworks (e.g., FDA OTC Homeopathic Drug Products Guidance); the TxGNN repurposing framework is not designed to evaluate these.
- **Resolve data gaps DG001 and DG002**: Safety warnings and MOA cannot be obtained until the product identity is confirmed.
- **Exclude from current pipeline**: Unless decomposed into individual components, this entry should be flagged as **out-of-scope** for the TxGNN drug repurposing workflow and removed from the active candidate queue.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

